Attorney's Docket No.: 10448-201001 / MPI03-005P1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jeffrey S. Ross Art Unit: 3736
Serial No.: 10/736,112 Examiner: Unknown

Filed: December 15, 2003

Title : METHODS OF DIAGNOSING AND TREATING CANCER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449.

In accordance with the PTO's waiver of 37 CFR 1.98 (a)(2)(i) for applications filed after

June 30, 2003, only copies of foreign patent documents and/or non-patent literature are enclosed.

This statement is being filed before the receipt of a first Office action on the merits.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 20 July 20

Rolando Medina Ph.D. Reg. No. 54,756

Fish & Richardson P.C. 225 Franklin Street

Boston, MA 02110-2804 Telephone: (617) 542-5070 Facsimile: (617) 542-8906

20888759.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate

(Modified)

Substitute form PTO-1449

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 10448-201001

Application No. 10/736,112

Information Disclosure Statement by Applicant (Use several sheets if necessary)

Jeffrey S. Ross

Applicant

Filing Date

December 15, 2003

Group Art Unit

(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner	Desig.	Document	Publication				Filing Date
Initial	ID	Number	Date	Patentee	Class	Subclass	If Appropriate
	AA	4,454,106	Gansow et al.	June 12, 1984]
	AB	4,472,509	Gansow et al.	September 18, 1984			
	AC	4,814,275	Durda et al.	March 21, 1989			
	AD	4,855,353	Kurami et al.	August 8, 1989			
	AE	4,863,851	McEwan et al.	September 5, 1989			
	AF	4,863,854	Mattes et al.	September 5, 1989			
<u>.</u>	AG	4,885,363	Tweedle et al.	December 5, 1989			
	AH	5,013,645	Kim	May 7, 1991			
	AI	5,053,503	Dean et al.	October 1, 1991			
	AJ	5,057,302	Johnson et al.	October 15, 1991			
	AK	5,118,611	Smith et al.	June 2, 1992			
	AL	5,130,118	Johnson et al.	July 14, 1992			
	AM	5,162,504	Horoszewicz	November 10, 1992			
	AN	5,198,208	Berg et al.	March 30, 1993			
	AO	5,208,324	Klaveness et al.	May 4, 1993			
	AP	5,217,704	Johnson et al.	June 8, 1993			
	AQ	5,227,471	Wright, Jr.	July 13, 1993			
	AR	5,229,289	Kjeldsen et al.	July 20, 1993			
	AS	5,314,996	Wright, Jr.	May 24, 1994			
	AT	5,342,924	Chang	August 30, 1994			
	AU	5,419,893	Berg et al.	May 30, 1995			
	AV	5,474,756	Tweedle et al.	December 12, 1995			
	AW	5,489,525	Pastan	February 6, 1996			
	AX	5,531,978	Berg et al.	July 2, 1996			
	AY	5,538,866	Israeli et al.	July 23, 1996	1		
	AZ	5,565,562	Parker et al.	October 15, 1996			

Exa	miner	Signa	ature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-201001	Application No. 10/736,112	
	closure Statement oplicant	Applicant Jeffrey S. Ross		
(Use several sheets if necessary)		Filing Date	Group Art Unit	
(37 CFR §1.98(b))		December 15, 2003		

•			U.S. Pate	ent Documents			
Examiner	Desig.	Document	Publication	Detecto	Class	0	Filing Date
Initial	ID	Number 5,578,484	Date Horoszewicz	Patentee November 26, 1996	Class	Subclass	If Appropriate
	AAA	5,599,677	Dowell et al.	February 4, 1997			
	ABB						
	ACC	5,639,879	Mease et al.	June 17, 1997			
	ADD	5,660,827	Thorpe et al.	August 26, 1997			
	AEE	5,674,470	Tweedle et al.	October 7, 1997			
	AFF	5,697,902	Goldenberg	December 16, 1997			
	AGG	5,763,202	Horoszewicz	June 9, 1998		***********	
	АНН	5,776,427	Thorpe et al.	July 7, 1998			
	AII	5,804,602	Slusher et al.	September 8, 1998			
	AJJ	5,846,519	Tweedle et al.	December 8, 1998			
	AKK	5,855,866	Thorpe et al.	January 5, 1999			
•••	ALL	5,863,538	Thorpe et al.	January 26, 1999			
	AMM	5,877,289	Thorpe et al.	March 2, 1999			
	ANN	5,935,818	Israeli et al.	August 10, 1999			
	AOO	5,958,474	Lee et al.	September 28, 1999			
	APP	5,965,132	Thorpe et al.	October 12, 1999		_	
	AQQ	6,004,554	Thorpe et al.	December 21, 1999			
	ARR	6,004,555	Thorpe et al.	December 21, 1999		<u>**,, </u>	
	ASS	6,022,524	Maisano et al.	February 8, 2000			
	ATT	6,036,955	Thorpe et al.	March 14, 2000			
	AUU	6,051,230	Thorpe et al.	April 18, 2000			
	AVV	6,093,399	Thorpe et al.	July 25, 2000			
	AWW	6,107,090	Bander	August 22, 2000			
	AXX	6,136,311	Bander	October 24, 2000	 		
	AYY	6,143,274	Tweedle et al.	November 17, 2000	+		
	AZZ	6,150,508	Murphy et al.	November 21, 2000		,	
	AAAA	6,261,535	Thorpe et al.	July 17, 2001			

Examiner Signature	Date Considered
:	
EVAMINED. Initials situation considered Describes the second situation if	A language and a standard and ball and a standard a

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office Information Disclosure Statement by Applicant

Jeffrey S. Ross

(Use several sheets if necessary)

Filing Date Group Art Unit December 15, 2003

(37 CFR §1.98(b))

	U.S. Patent Documents						
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	ABBB	6,331,175	Goldenberg	December 18, 2001			
	ACCC	6,649,163	Bander	November 18, 2003		-	

	Foreig	n Patent Doo	uments or P	ublished Foreign	Patent A	Application	าร	
Examiner	Desig.	Document	Publication	Country or			Trans	slation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	ADDD	WO 86/06384	11/ 1986	PCT				
	AEEE	WO 88/02635	04/ 1988	PCT				
	AFFF	WO 89/00557	01/ 1989	PCT				
***	AGGG	WO 89/06979	08/ 1989	PCT				
	АННН	WO 91/15466	10/ 1991	PCT				
	AIII	WO 93/17715	09/ 1993	PCT				
7-2-4	AJJJ	WO 93/19668	10/ 1993	PCT				
	AKKK	WO 94/04702	03/ 1994	PCT				
	ALLL	WO 94/09820	05/ 1994	PCT				
	AMMM	WO 94/26297	11/ 1994	PCT				
·	ANNN	WO 95/26206	10/ 1995	PCT				
	A000	WO 95/31444	11/ 1995	PCT				
	APPP	WO 96/26272	08/ 1996	PCT				
	AQQQ	WO 96/39185	12/ 1996	PCT				
	ARRR	WO 96/40245	12/ 1996	PCT				
	ASSS	WO 97/32862	09/ 1997	PCT				
	ATTT	WO 97/35616	10/ 1997	PCT				
	AUUU	WO 99/43710	09/ 1999	PCT				
	AVVV	WO 00/50457	08/ 2000	PCT		,		
	AWWW	WO 00/52473	09/ 2000	PCT				
	AXXX	WO 00/74729	12/ 2000	PCT			_	

Examiner Signature	Date Considered
-xarmior digitatare	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-201001	Application No. 10/736,112	
	closure Statement oplicant	Applicant Jeffrey S. Ross		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date December 15, 2003	Group Art Unit	

	Foreig	n Patent Doo	uments or P	ublished Foreign F	Patent A	Application	าร	
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AYYY	EP 0 208 531 B1	01/ 1987	Europe				
	AZZZ	EP 0 232 751 B1	08/ 1987	Europe				
	AAAAA	EP 0 233 619 B1	08/ 1987	Europe				
	ABBBB	EP 0 279 397 B1	08/ 1988	Europe				
	ACCCC	EP 0 292 689 B1	11/ 1988	Europe				
	ADDDD	EP 0 299 795 A1	01/ 1989	Europe				
	AEEEE	EP 0 315 188 B1	05/ 1989	Europe				
	AFFFF	EP 0 382 583 B1	08/ 1990	Europe				
	AGGGG	EP 0 392 423 A2	10/ 1990	Europe				
	АННН	EP 0 466 200 A1	01/ 1992	Europe				
	AIIII	EP 0 594 739 B1	05/ 1994	Europe				
	AJJJJ	EP 0 882 454 A2	12/ 1998	Europe				
	AKKKK	NZ333683	01/2002	New Zealand				

	Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document				
	ALLLL	ATCC Deposit #HB9131 from June 24, 1986 (NOT AVAILABLE)				
AMMMM Barren et al. (1997), "Monoclonal Antibody 7E11.C5 Staining of Viable LNCaP Cells", Prosta 30(1):65-68.						
	ANNNN	Carter et al. (1996), "Prostate-specific Membrane Antigen is a Hydrolase with Substrate and Pharmacologic Characteristics of a Neuropeptidase", Proc. Natl. Acad. Sci. U.S.A. 93:749-753.				
	A0000	Chang et al. (1999), "Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature", Cancer Research, 59(13):3192-3198.				
	APPPP	Diamond et al. (1997), "Monoclonal Antibody 225 Blockade of Prostate Specific Membrane Antigen (PSM) Expression: Potential Novel Therapy for Prostate Cancer", Journal of Urology 157(4 suppl):226 (Abstract 884).				

Examiner Signature	Date Considered			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-201001	Application No. 10/736,112
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Jeffrey S. Ross	
		Filing Date December 15, 2003	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	AQQQQ	Dillman et al. (1988), "Toxicities Associated with Monoclonal Antibody Infusions in Cancer Patients", Mol. Biother. 1(2):81-85.	
	ARRRR	Dillman et al. (1994), "Human Anti-Mouse Antibody Response in Cancer Patients Following Single Low-Dose Injections of Radiolabeled Murine Monoclonal Antibodies", Cancer Biotherapy 9(1):17-28.	
	ASSSS	Fair et al. (1997), "Prostate Specific Membrane Antigen", Prostate 32(2):140-148.	
	АТТТТ	Harlow and Lane (1988), "Antibodies: A laboratory manual", Cold Spring Harbor Laboratory, p139-243.	
	AUUUU	Heston (1997), "Characterization and Glutamyl Preferring Carboxypeptidase Function of Prostate Specific Membrane Antigen: A Novel Folate Hydrolase", Urology 49(3A):104-112.	
•	AVVVV	Horoszewicz et al. (1987), "Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients", Anticancer Research 7(5B):927-936.	
	AWWWW	Israeli et al. (1993), "Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen", Cancer Research 53(2):227-230.	
	AXXXX	Israeli et al. (1994), "Expression of the Prostate-Specific Membrane Antigen", Cancer Research 54(7):1807-1811.	
	AYYYY	Israeli et al. (1997), "Prostate Specific Membrane Antigen and Other Prostatic Tumor Markers on the Horizon", Urological Clinics of North America 24(2):439-450.	
	AZZZZ	Jain, R.K. (1990), "Vacular and interstitial barriers to delivery of therapeutic agents in tumors", Cancer and Metastasis Reviews 9(3):253-266.	
	AAAAA	Leek et al. (1995), "Prostate-Specific Membrane Antigen: Evidence for the Existence of a Second Related Human Gene", British Journal of Cancer 72:583-588.	
	ABBBBB	Leung et al. (1986), "Selection of a Monoclonal Antibody to a New Prostate Cancer Marker for In Vivo Clinical Trials", 6 th International Congress of Immunology, p516 (Abstract 4.15.19).	
	ACCCCC	Liu et al. (1997), "Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen also React with Tumor Vascular Endothelium", Cancer Research 57(18):3629-3634.	
	ADDDDD	Liu, et al. (1998), "Constitutive and Antibody-Induced Internalization of Prostate-Specific Membrane Antigen", Cancer Research 58(18):4055-4060.	
	AEEEEE	Murphy et al. (1995), "Comparison of Prostate Specific Antigen, Prostate Specific Membrane Antigen, and LNCaP-Based Enzyme-Linked Immunosorbent Assays in Prostatic Cancer Patients and Patients With Benign Prostatic Enlargement", The Prostate 26:164-168.	
	AFFFFF	Murphy et al. (1995), "Comparison of Prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients", Anticancer Res. 15:1473-1480.	

Examiner Signature	Date Considered	
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-201001	Application No. 10/736,112
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Jeffrey S. Ross	
		Filing Date December 15, 2003	Group Art Unit

	Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document	
	AGGGGC	Murphy et al. (1996), "Measurement of Prostate-Specific Membrane Antigen in the Serum With a New Antibody", The Prostate 28(4):266-271.	
	АНННН	Pinto et al. (1996), "Prostate-Specific Membrane Antigen: A Novel Folate Hydrolase in Human Prostatic Carcinoma Cells", Clincal Cancer Research 2(9):1445-1451.	
	AIIIII	Rochon et al. (1994), "Western Blot Assay for Prostate-Specific Membrane Antigen in Serum of Prostate Cancer Patients", The Prostate 25(4):219-223.	
	AJJJJJ	Schlom (1991), "Monoclonal antibodies: They're more and less than you think", Molecular Foundations of Oncology, ed. Broder, Williams & Wilkins, p95-134.	
	AKKKKK	Silver et al. (1997), "Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues", Clinical Cancer Research 3:81-85.	
	ALLLLL	Su et al. (1995), "Alternatively Spliced Variants of Prostate-specific Membrane Antigen RNA: Ratio of Expression as a Potential Measurement of Progression", Cancer Research 55:1441-1443.	
	<i>Р</i> ММММІ	Troyer et al. (1994), "Subcellular Localization of the 7E11-C5 Prostate Specific Antigen", Proc. Am. Assoc. Cancer Research 35:283 (Abstract 1688).	
	ANNNN	Troyer et al. (1995), "Biochemical Characterization and Mapping of the 7E11-C5.3 Epitope of the Prostate-Specific Membrane Antigen", Urol Oncol 1:29-37.	
	A00000	Troyer et al. (1995), "Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids", International Journal of Cancer 62(5):552-558.	
	APPPPP	Troyer et al. (1997), "Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line", Prostate 30(4):232-242.	
	AQQQQQ	Uria et al. (1997), "Prostate Specific Membrane Antigen in Breast Carcinoma", The Lancet 349(9065):1601.	
	ARRRRR	Wang et al. (1988), "Monoclonal Antibody Assays for Prostatic Tumor", Immunol Ser 39:195-219.	
	ASSSSS	Wright (1990), "Characterization of a New Prostate Carcinoma-Associated Marker: 7E11-C5", Antibody Immunoconjugates and RadioPharmaceuticals 3:Abstract 193.	
	ATTTTT	Malignant Prostate Tissues", Urol Oncol, 1:18-28.	
	AUUUUL	Yang et al. (1998), "Alpha particle emitter therapy of micrometastases: ²¹³ Bi-J5 (anti-PSMA) treatment of LNCaP spheroids", Proceedings of the American Association for Cancer Research 39:440 (Abstract #2996).	

Examiner Signature	Date Considered	
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		